| abstract |
The invention encompasses a PRLR binding protein. In particular, the invention relates to antibodies which are chimeric, CDR-grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity both in vitro and in vivo. The antibody of the present invention may be a full length antibody or an antigen binding portion thereof. Methods of using the antibodies of the invention and methods of use are also provided. The antibody or antibody portion of the invention is useful for detecting hPRLR and, for example, inhibiting hPRLR activity in a human subject suffering from a condition in which hPRLR activity is detrimental. The invention also includes anti-PRLR antibody drug conjugates (ADCs). |